Jeremiah B. Frueauf is a director and chair of Sterne Kessler’s Biotechnology & Chemical Practice Group, delivering strategic patent counsel to clients at the forefront of the life sciences sector. Jeremiah advises domestic and international clients on patent procurement, product development and clearance strategies, and protection of complex worldwide patent portfolios. He is particularly focused on helping clients maximize the value of their intellectual property, advising on freedom-to-operate, patentability, validity, and infringement issues, and performing due diligence investigations in connection with financings, acquisitions, and other investments.

Jeremiah’s IP due diligence evaluation and counseling are critical to his clients’ businesses in the context of raising and investing growth capital, executing strategic partnerships, and supporting M&A transactions and going public. Representative recent matters in which he served as IP lead include:

Represented licensee company acquiring exclusive licenses and development rights for two small molecule assets in late clinical development for treatment of metabolic disorders, including type 2 diabetes, for deals valued at $20 million upfront and $513.8 million in milestones and $35 million upfront and $615 million in milestones.

•             Represented company acquiring exclusive licenses and development rights for spin-out RNA therapeutics company jointly owned with patent owner for deal involving $37.5 million in transaction-related seed capital. Involved technology included RNA lipid delivery platform.

•             Represented venture funds in $30 million Series B financing for biologic asset in clinical development for metastatic bladder cancer.

•             Represented acquired company for dermatological therapeutic in mid-stage clinical development for deal valued at $229 million upfront and $618 million in milestones.